Aug 28 (Reuters) -
Neurocrine Biosciences ( NBIX ) said on Wednesday its
experimental drug to treat adults with schizophrenia met the
main goal in a mid-stage study.
(Reporting by Mariam Sunny in Bengaluru; Editing by Sriraj
Kalluvila)